The Shenzhen, China-based biotech plans to launch a Phase I trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IN026.

Management projects 2026 total revenue of $78 million to $83 million, including the anticipated $25 million milestone from Chiesi. Expected revenue from Chiesi is $33 million to $35 million, ...

People who take GLP-1 medications for several years may face a higher risk of developing osteoporosis, gout, and osteomalacia, according to new research presented Monday at the an ...

The CNBC Cures Summit, held in New York earlier this week, opened with a simple but urgent premise: every step forward changes someone’s life. Moderator Becky Quick set the tone by explaining that ...

Annual stadium concert brings tens of thousands together in San Diego for unforgettable night of music and impact to raise funds for cancer research. Curebound, a philanthropic organization that funds ...

Mary started drinking regularly in the early nineties, when she was thirteen. Her father had recently married a Danish woman and moved the family to Denmark, which has one of the highest teen-drinking ...

Diet can also be a key factor in the development of gout. Avoiding foods high in purines, such as red meat, can help lower risk. Medications taken to treat gout can help people with that condition ...

Medications taken to treat gout can help people with that condition reduce their risk of heart attack and stroke. That’s the conclusion of a new research analysis recently published in JAMA Internal ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. 12, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The oncology landscape is entering a high-velocity regulatory phase as ...

Enolen's fast track designation by the FDA aims to expedite its development for localized prostate cancer treatment, addressing unmet medical needs. The localized delivery technology targets ...

Becky Quick outlines her daughter's personal struggle with SYNGAP1. Quick explains why her daughter's journey inspired her to launch CNBC Cures. I've spent the last 25 years in front of the camera ...